Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

It can detect drusen, lipids, crystalline deposits and pigmentation alterations, all of which are associated with early stages of AMD, as well as hemorrhages, fluid, exudates, atrophy and fibrosis ...

The sponsor of two phase 3 clinical trials of an add-on agent to treat age-related macular degeneration has decided to halt both trials after they showed the add-on treatment did not outperform ...

Age-related macular degeneration (AMD) is the leading cause of blindness among older adults. The exudative or ‘wet’ form of the disease is characterized by the growth of abnormal blood vessels from ...

As AMD progressed, these drusen could lead to disruptions in the foveal architecture and potential fluid accumulation beneath the retina. DME was characterized by the presence of hard exudates ...

Background To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab. Methods The study ...